Pfizer Axes Deal For Brain Cancer Vaccine, Leaves Partner Celldex In the Lurch
This article was originally published in The Pink Sheet Daily
Executive Summary
A brave face: Celldex execs say they are ready and able to take brain cancer vaccine CDX-110 into Phase III without a Big Pharma partner.
You may also be interested in...
With Geron Deal Done, AngioChem Turns To Its Own Pipeline
A $35 million agreement gets Geron a cancer drug that can cross the blood brain barrier - and gives AngioChem financial runway for its own pursuits.
With Geron Deal Done, AngioChem Turns To Its Own Pipeline
A $35 million agreement gets Geron a cancer drug that can cross the blood brain barrier - and gives AngioChem financial runway for its own pursuits.
Celldex To Fly Solo With Phase III Trial Of Brain Cancer Vaccine
All on its own, Celldex is gearing up to run a Phase III trial in the second half of 2011, testing its therapeutic cancer vaccine rindopepimut in newly diagnosed glioblastoma, after releasing positive results from ACT III, the last of three trials in its Phase II program.